2026 Practice-Changing Updates in Bladder, Kidney, & Prostate Cancers

Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this 2026 program brings together leading experts in genitourinary oncology to share the latest strategies for managing localized and advanced bladder, kidney, and prostate cancers. With rapid advances in systemic therapy, surgical innovation, radiation technology, and biomarke-driven decision-making, clinicians are navigating an increasingly complex treatment landscape.
This year’s program highlights first line intensification in metastatic prostate cancer, perioperative chemoimmunotherapy for muscle-invasive bladder cancer, evolving targeted approaches in renal cell carcinoma, and updated frameworks guiding treatment selection in non-muscle invasive bladder cancer. Faculty will emphasize how to integrate these innovations into everyday practice through multidisciplinary coordination. Through expert lectures, panel discussions, and case-based sessions, participants will gain practical insights they can apply directly in clinical care.
PROGRAM DATE: Wednesday, November 18, 2026
TIMES:
5:30–6:45 pm EST Check-In and Reception
(Buffet opens at 6:30)
7:00–9:00 pm EST CME & Dinner
LOCATION:
Philadelphia Marriott Old City
One Dock Street
Philadelphia, PA 19106
PROGRAM DIRECTORS

Fern M. Anari, MD
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center

Andres F. Correa, MD
Associate Professor & Director of Research,
Department of Urology
Society of Urologic Oncology Fellowship Program Director
Fox Chase Cancer Center
Fox Chase – Temple Urologic Institute Provider
TOPICS & SPEAKERS
Welcome and Overview: What Changed in GU Oncology in 2026?
Fern M. Anari, MD and Andres F. Correa, MD
Metastatic Prostate Cancer: Treatment Intensification, Biomarkers and New Therapeutic Strategies
Daniel M. Geynisman, MD
Muscle-Invasive Bladder Cancer: Perioperative Therapy and the Evolving Treatment Algorithm
Pooja Ghatalia, MD
Renal Cell Carcinoma: Emerging Evidence and Treatment Sequencing
Gregory Hemenway, MD
Urologic Oncology Update: New Approaches in Prostate and Bladder Cancer
Andres F. Correa, MD
Localized Prostate Cancer: Biomarker Integration and Selective Radiation Volume
Hilario Yankey, MD
Multidisciplinary Case Challenge: Putting the 2026 Evidence into Practice
Moderators: Fern M. Anari, MD and Andres F. Correa, MD
Panelists: Daniel M. Geynisman, MD, Pooja Ghatalia, MD, Gregory Hemenway, MD, and Hilario Yankey, MD
Educational Objectives: Upon completion of this activity, participants should be able to:
- Select appropriate treatment intensification strategies for metastatic prostate cancer, incorporating disease volume, patient fitness, biomarkers, and emerging PSMA-directed approaches.
- Evaluate perioperative treatment strategies for high-risk localized prostate cancer, incorporating new evidence from the PROTEUS trial and implications for surgical management.
- Integrate contemporary perioperative systemic therapies into the management of muscle-invasive bladder cancer, including the emerging role of ctDNA/MRD in treatment decision-making.
- Apply updated risk stratification and treatment approaches for non-muscle-invasive bladder cancer (NMIBC) when selecting bladder-sparing therapies, radical cystectomy, or clinical trials.
- Evaluate and sequence contemporary therapies for renal cell carcinoma, including new combinations in adjuvant and advanced disease settings.
- Identify evolving applications of radiation therapy in genitourinary malignancies, including integration with systemic and surgical treatment strategies.
- Apply a multidisciplinary, evidence-based approach to treatment selection across prostate, bladder, and kidney cancers.
INTENDED AUDIENCE: This program is designed for urologists; medical, radiation and surgical oncologists; radiologists; primary care physicians; fellows/residents/students; nurses; nurse practitioners; advanced practice providers; and all healthcare professionals involved in the care of patients with bladder, kidney, or prostate cancer.
ACCREDITATION STATEMENT: The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
DESIGNATION STATEMENT:The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.
INQUIRIES: Lucía Tono, PhD, MEd
Lucia.Tono-Ramirez@tuhs.temple.edu
EXHIBITOR INFORMATION: Contact Lisa Bailey to learn about opportunities to exhibit at this event at 215-872-5846 or Lisa.Bailey@fccc.edu.


